Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts that appear to support the survival and growth of malignant tumors.

October 10, 2025

Vol.51 No.37

In Brief

Alessio Pigazzi, expert in robot-assisted techniques, selected as new colorectal surgery leader at Cedars-Sinai

Alessio Pigazzi was chosen to lead the newly created faculty division of colorectal surgery in the Jim and Eleanor Randall Department of Surgery at Cedars-Sinai.

October 03, 2025

Vol.51 No.36

In Brief

The University of Cincinnati researchers win NCI grant to study combination colorectal cancer treatment

The University of Cincinnati Cancer Center’s Joan Garrett has received a two-year, $162,000 NCI grant to study a new combination approach to treat KRAS-mutated colorectal cancers.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.

September 26, 2025

Vol.51 No.35

Clinical Roundup

ALOX15 loss, common in CRC, impairs the cancer-preventative effects of fish oil, mouse study shows

About 19 million American adults consume dietary fish oil supplements. These supplements, which primarily consist of the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid, are widely used as a remedy for chronic diseases. However, the effects of EPA and DHA supplementation on cancer risk have been inconsistent.

September 26, 2025

Vol.51 No.35

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

YOU MAY BE INTERESTED IN

Zanzalintinib + atezolizumab improve survival in advanced CRC

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Alessio Pigazzi, expert in robot-assisted techniques, selected as new colorectal surgery leader at Cedars-Sinai

The University of Cincinnati researchers win NCI grant to study combination colorectal cancer treatment

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

ALOX15 loss, common in CRC, impairs the cancer-preventative effects of fish oil, mouse study shows

Renew today!

Subscriber content

Never miss an issue!

Login